- Home
- NVAX vs RCKT Comparison
NVAX vs RCKT Comparison
Compare NVAX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- RCKT
- Stock Information
- Founded
- NVAX 1987
- RCKT 1999
- Country
- NVAX United States
- RCKT United States
- Employees
- NVAX N/A
- RCKT N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- NVAX Health Care
- RCKT Health Care
- Exchange
- NVAX Nasdaq
- RCKT Nasdaq
- Market Cap
- NVAX 1.3B
- RCKT 264.0M
- IPO Year
- NVAX 1995
- RCKT N/A
- Fundamental
- Price
- NVAX $6.84
- RCKT $2.99
- Analyst Decision
- NVAX Buy
- RCKT Buy
- Analyst Count
- NVAX 5
- RCKT 13
- Target Price
- NVAX $16.60
- RCKT $18.50
- AVG Volume (30 Days)
- NVAX 4.9M
- RCKT 3.8M
- Earning Date
- NVAX 08-07-2025
- RCKT 08-04-2025
- Dividend Yield
- NVAX N/A
- RCKT N/A
- EPS Growth
- NVAX N/A
- RCKT N/A
- EPS
- NVAX 2.97
- RCKT N/A
- Revenue
- NVAX $1,254,962,000.00
- RCKT N/A
- Revenue This Year
- NVAX $56.85
- RCKT N/A
- Revenue Next Year
- NVAX N/A
- RCKT N/A
- P/E Ratio
- NVAX $2.30
- RCKT N/A
- Revenue Growth
- NVAX 25.92
- RCKT N/A
- 52 Week Low
- NVAX $5.01
- RCKT $2.19
- 52 Week High
- NVAX $17.81
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- NVAX 51.12
- RCKT 45.55
- Support Level
- NVAX $6.54
- RCKT $2.76
- Resistance Level
- NVAX $7.20
- RCKT $3.24
- Average True Range (ATR)
- NVAX 0.28
- RCKT 0.19
- MACD
- NVAX 0.06
- RCKT 0.17
- Stochastic Oscillator
- NVAX 66.36
- RCKT 74.85
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.